Are you ready to change the way you think?Ikonisys
The premier global leader
in FISH technology
"Ikonisys proudly stands as the premier global leader in FISH (Fluorescent In Situ Hybridization) technology, solidifying its position as the foremost manufacturer and provider of state-of-the-art solutions for genetic analysis.
With a relentless commitment to innovation, precision, and reliability, Ikonisys continuously sets the industry standard, empowering laboratories worldwide with unparalleled tools and expertise to advance scientific research, diagnosis, and treatment across a myriad of genetic disorders and diseases."
With a relentless commitment to innovation, precision, and reliability, Ikonisys continuously sets the industry standard, empowering laboratories worldwide with unparalleled tools and expertise to advance scientific research, diagnosis, and treatment across a myriad of genetic disorders and diseases."
WE FIND THE CELLS THAT MATTER
A combination of proprietary instrument, software applications and reagents with
International Patents
We are a scientific company.
Our effort is to create innovations to deliver the best productivity to our clients.
Our effort is to create innovations to deliver the best productivity to our clients.
AUTOMATED FISH CANCER DIAGNOSTIC
The automated screening of biological tissue for gene abnormalities using an automated fluorescence microscope to analyze fluorescence in situ hybridized (FISH) samples is provided.
CTC AUTOMATED SCANNING AND DETECTION
An automated, highly sensitive, specific and potentially quantitative detection method using an automated microscope for identifying and enumerating rare cancer cells in blood and other fluids.
COMPUTER CONTROLLED RARE CELL DIAGNOSIS
A computer controlled method for detecting and diagnosing a rare cell type in a tissue sample.
HIGH GRADE HYPERPLASIA AUTOMATED DETECTION
An automated method for monitoring the efficacy over time of therapy of a cancer or hyperplasia in a patient. Provides an approach for treatment monitoring, determining response to therapy.
COMPUTER AUTOMATED IMAGE ANALYSIS
An approach to perform various image processing functions which may be employed to implement the automated fluorescence in situ hybridization method.
MULTIPLE SUBCELLULAR QUANTITATING
A method that combines immunohistochemistry and fluorescence in situ hybridization techniques, for detecting and quantitating multiple and unique fluorescent signals from a cell sample.
IMAGER SYSTEM GAIN CONTROL
An imaging system comprising an image intensifier and a CMOS image sensor, that provides fast capture speed and high sensitivity. Enables both the capture speed and sensitivity requirements for automated microscopy designed to detect signals in a biological sample.
AUTOMATED MICROSCOPE SLIDE READ SYSTEM
Automated microscopic analysis of a plurality of data-encoded microscope slides. The data written to or read from the slides may comprise images, analysis protocols, analytic results and other clinically relevant data.
Dedicated to
Pathologists
Fluorescence In Situ Hybridization technology provides a high level of sensitivity and specificity in detecting genetic abnormalities, allowing for precise identification of chromosomal alterations associated with various cancers.
This aids in accurate cancer diagnosis and classification.
FISH enables pathologists to analyze tumor heterogeneity, providing valuable insights into tumor biology and prognosis. By visualizing specific genetic markers, pathologists can predict disease progression and tailor treatment strategies accordingly.
It is particularly useful in monitoring treatment responses and detecting minimal residual disease, helping pathologists assess treatment efficacy and guide patient management decisions.
Overall, the use of FISH technology empowers pathologists with valuable diagnostic and prognostic information, ultimately leading to improved patient care and outcomes in oncology.
This aids in accurate cancer diagnosis and classification.
FISH enables pathologists to analyze tumor heterogeneity, providing valuable insights into tumor biology and prognosis. By visualizing specific genetic markers, pathologists can predict disease progression and tailor treatment strategies accordingly.
It is particularly useful in monitoring treatment responses and detecting minimal residual disease, helping pathologists assess treatment efficacy and guide patient management decisions.
Overall, the use of FISH technology empowers pathologists with valuable diagnostic and prognostic information, ultimately leading to improved patient care and outcomes in oncology.
We keep in mind
TECHNICIANS
Automation streamlines and standardizes the FISH process, reducing the potential for human error and variability in results. This ensures greater consistency and accuracy in diagnostic testing.
Automation increases efficiency and throughput, allowing technicians to analyze a larger volume of samples in a shorter amount of time. This is particularly beneficial in high-volume laboratories where rapid turnaround times are essential for patient care. It minimizes manual labor and repetitive tasks, reducing technician fatigue and freeing up time for more complex analyses and interpretation of results. It also optimizes workflow management, enabling technicians to focus on critical aspects of the FISH procedure.
Additionally, automation enhances traceability and documentation, providing a comprehensive record of each step in the testing process. This facilitates quality control and regulatory compliance, ensuring adherence to strict laboratory standards.
Automation increases efficiency and throughput, allowing technicians to analyze a larger volume of samples in a shorter amount of time. This is particularly beneficial in high-volume laboratories where rapid turnaround times are essential for patient care. It minimizes manual labor and repetitive tasks, reducing technician fatigue and freeing up time for more complex analyses and interpretation of results. It also optimizes workflow management, enabling technicians to focus on critical aspects of the FISH procedure.
Additionally, automation enhances traceability and documentation, providing a comprehensive record of each step in the testing process. This facilitates quality control and regulatory compliance, ensuring adherence to strict laboratory standards.
A Unique opportunity
Oncology Diagnostic Labs
As precision medicine becomes increasingly prevalent in healthcare, there is a growing demand for diagnostic technologies like FISH that provide personalized insights into disease biology. FISH enables the detection of specific genetic abnormalities associated with various diseases, including cancer, guiding treatment decisions and improving patient outcomes.
Also, with the rising incidence of cancer worldwide, the oncology market continues to expand. FISH plays a crucial role in cancer diagnostics, prognosis, and treatment selection, making it a valuable asset for oncology laboratories and healthcare providers.
Ikonisys FISH technology, incorporates embedded automation, multiplexing, and digital imaging, enhance workflow efficiency, accuracy, and scalability. These technological innovations make FISH more accessible and cost-effective, opening up new market opportunities.
Also, with the rising incidence of cancer worldwide, the oncology market continues to expand. FISH plays a crucial role in cancer diagnostics, prognosis, and treatment selection, making it a valuable asset for oncology laboratories and healthcare providers.
Ikonisys FISH technology, incorporates embedded automation, multiplexing, and digital imaging, enhance workflow efficiency, accuracy, and scalability. These technological innovations make FISH more accessible and cost-effective, opening up new market opportunities.
Why
FISH is the most versatile technology for cancer diagnostics?
FISH technology is considered the best for cancer diagnostics due to its high sensitivity and specificity in detecting genetic abnormalities. It allows for the precise identification of chromosomal alterations, such as translocations, amplifications, and deletions, which are often linked to specific types of cancer. This enables accurate diagnosis, prognosis, and prediction of treatment responses, making FISH an invaluable tool in personalized cancer care.
For diagnostic purposes
Certain chromosomal abnormalities have been identified in numerous patients and now serve to define specific cancer diagnoses. For instance, a subtype of acute myeloid leukemia known as acute promyelocytic leukemia is characterized by the translocation between chromosomes 15 and 17.
For prognosis
Our applications have many options that you can customize as you wish.
For predicting response to therapy
Determine the most apropriate therapeutic approach for any patient.
For surveillance
Monitor the success of the chosen therapy
A unique fully-automated solution for diagnostic laboratories Revolutionizing
laboratory workflow
through full automation
A fully-automated high-speed Fluorescence Microscopy Platform
optimized for the identification, analysis and enumeration of rare
cells in a biological sample
optimized for the identification, analysis and enumeration of rare
cells in a biological sample
Proprietary Tecnology
20 years of R&D and Fine Tuning
New features Ikoniscope
Exploring the latest advancements in microscopy reveals a range of exciting new features designed to enhance imaging capabilities, improve user experience, and expand research possibilities. From cutting-edge imaging techniques to user-friendly software interfaces, here are some of the innovative features found in modern microscopes
Lightning fast camera
The introduction of new high-resolution cameras for microscopes represents a significant advancement in imaging technology, offering researchers enhanced capabilities for capturing detailed images of biological samples. These state-of-the-art cameras boast several innovative features
Smart web based connectivity
Remote Access and Control: Smart web-based connectivity allows researchers to remotely access and control microscope systems from any location with an internet connection. This enables users to conduct experiments, adjust imaging parameters, and analyze data without being physically present in the laboratory.
Stay ahead of the curve Lead the field in
genetic diagnostics with
our state-of-the-art FISH platform.
Elevate your laboratory's performance and achieve superior results with the most advanced FISH solution available.
The 3 Pillars
of Ikonisys FISH
Our research and development endeavors were guided by a consistent underlying philosophy, grounded in a set of core beliefs that we firmly adhere to and trust.
Automation
The integration of automation in FISH technology empowers technicians with improved efficiency, consistency, and quality in diagnostic testing, ultimately leading to enhanced patient care outcomes.
Digitization
Acquire fluorescence images of all the desired cells or tissue present on the slide and the diagnostic signals that they contain.
Analysis & Interpretation
Analyze and interpret the acquired images in a both qualitative and quantitative fashion; enumerating, classifying and presenting diagnostically relevant cells for review, without user intervention, as an adjunct to diagnosis
Compliance and Qualitycertified for
TOTAL RELIABILITY
The company has achieved significant milestones in regulatory clearance, quality assurance, and compliance within the healthcare sector.
Obtaining FDA clearance for multiple diagnostic applications in the USA and securing CE certification for distribution in Europe demonstrate its commitment to meeting rigorous regulatory standards across diverse markets.
Adhering to ISO13485 compliance ensures robust quality management systems for medical devices, affirming the company's dedication to delivering safe and effective products.
Additionally, its FDA registration as a Medical Device Manufacturer underscores its accountability and reliability in providing innovative diagnostic solutions that meet regulatory requirements and address evolving healthcare needs.
Obtaining FDA clearance for multiple diagnostic applications in the USA and securing CE certification for distribution in Europe demonstrate its commitment to meeting rigorous regulatory standards across diverse markets.
Adhering to ISO13485 compliance ensures robust quality management systems for medical devices, affirming the company's dedication to delivering safe and effective products.
Additionally, its FDA registration as a Medical Device Manufacturer underscores its accountability and reliability in providing innovative diagnostic solutions that meet regulatory requirements and address evolving healthcare needs.
Our satisfied
clients
Thank you for choosing our FISH system.
We look forward to continuing to serve you and to contributing to your success in the field of genetic analysis.
We look forward to continuing to serve you and to contributing to your success in the field of genetic analysis.
More than 300.000
FISH test done
Our advanced genetic testing platform has undergone extensive validation in thousands of real-world scenarios, confirming its reliability across a wide range of conditions and applications.
From disease diagnosis to personalized medicine, our platform has been proven to deliver consistent and accurate results, providing peace of mind to both healthcare professionals and patients alike.
0123456789001234567890
Scientist, Reserachers and Engineers
0123456789001234567890
Years of Develoment and experience
0123456789001234567890 .012345678900123456789001234567890
Hours of testing and fine tuning
With our commitment to excellence and quality assurance, you can trust that our genetic testing platform will meet your highest standards for reliability and accuracy. Experience the difference that thousands of tests performed can make with Ikonisys. Contact us today to learn more.
FISH means
Early Cancer Diagnostics
Early cancer diagnosis is crucial for several reasons.
First and foremost, it significantly increases the chances of successful treatment and improves patient outcomes. Detecting cancer at an early stage allows for timely intervention, which can often result in less aggressive treatments and better prognosis.
Additionally, early diagnosis can help prevent cancer from spreading to other parts of the body, potentially reducing the need for extensive and invasive procedures. Moreover, it can lead to a better quality of life for patients and their families by minimizing the physical, emotional, and financial burden associated with advanced-stage cancer.
Overall, early cancer diagnosis plays a pivotal role in saving lives and enhancing the overall effectiveness of cancer care.
FISH technology in mass screening application has the potential to save millions of human lives.
First and foremost, it significantly increases the chances of successful treatment and improves patient outcomes. Detecting cancer at an early stage allows for timely intervention, which can often result in less aggressive treatments and better prognosis.
Additionally, early diagnosis can help prevent cancer from spreading to other parts of the body, potentially reducing the need for extensive and invasive procedures. Moreover, it can lead to a better quality of life for patients and their families by minimizing the physical, emotional, and financial burden associated with advanced-stage cancer.
Overall, early cancer diagnosis plays a pivotal role in saving lives and enhancing the overall effectiveness of cancer care.
FISH technology in mass screening application has the potential to save millions of human lives.
Liquid biopsy / CTC
Circulating Tumor Cells
CTC (Circulating Tumor Cells) analysis is crucial in cancer research and treatment, offering a non-invasive method for early detection, monitoring disease progression, and tailoring personalized therapeutic strategies.
Using FISH (Fluorescence In Situ Hybridization) technology for CTC (Circulating Tumor Cells) detection enhances the ability to identify and characterize genetic abnormalities in cancer cells, facilitating precise, non-invasive diagnosis and targeted treatment strategies.
Using FISH (Fluorescence In Situ Hybridization) technology for CTC (Circulating Tumor Cells) detection enhances the ability to identify and characterize genetic abnormalities in cancer cells, facilitating precise, non-invasive diagnosis and targeted treatment strategies.
Get in touch
Come and visit our quarters or simply send us an email anytime you want. We are open to all requests.
Address
5 Science Park, New Haven, Connecticut
06511 - USA
06511 - USA
Call us
+1.203.776.0791
corporate@ikonisys.com
IKONISYS
HOSPITEX
HEADQUARTERS
Ikonisys, Inc.
5 Science Park, New Haven, Connecticut 06511, USA
Phone: +1.203.776.0791
Email: corporate@ikonisys.com
FRANCE
Ikonisys, SA
62, rue de Caumartin
75009 Paris
Email: investors@ikonisys.com
ITALY
Ikonisys S.r.l.
Via dell’Ambrosiana,22
20123 Milano
Email: corporate@ikonisys.com
Copyright by Ikonisys Inc. All rights reserved.